Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Ap­pli­ca­tion Sub­mit­ted for Con­di­tion­al Mar­ket­ing Au­tho­ri­sa­tion of the COVID-19 Vac­cine VLA2001 from Val­ne­va

The company Valneva applied for a conditional marketing authorisation for its COVID-19 vaccine candidate VLA2001 with the European Medicines Agency (EMA) on 18 May 2022. The vaccine's rolling review procedure for the vaccine began on 2 December 2021. Since then, the pharmaceutical experts of the European national pharmaceutical authorities have been continuously evaluating the documents submitted during the procedure. The Committee for Medicinal Products for Human Use (CHMP) at the EMA is expected to decide in a few weeks on a possible recommendation for authorisation by the European Commission.

Coronavirus Vaccine Ampoules (Source: MPhoto/Shutterstock.com)

Background – Valneva's COVID-19 Vaccine VLA2001

The vaccine candidate from the French-Austrian company Valneva is a whole virus vaccine against COVID-19.

The virus is propagated in Vero cells. This is a cell line derived from kidney cells of the African green monkey. The viruses are inactivated after being cultivation. The vaccine contains two adjuvants: aluminium hydroxide, which is known as a component of some vaccines, and CpG 1018. CpG 1018 is also already present as an adjuvant in a hepatitis B vaccine approved in Europe.

Updated: 19.05.2022